{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+2&page=72",
    "query": {
      "intervention": "cohort 2",
      "page": 72
    },
    "page_size": 10
  },
  "pagination": {
    "page": 72,
    "page_size": 10,
    "total_count": 7392,
    "total_pages": 740,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+2&page=73&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+2&page=71&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-20T02:08:54.400Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03663218",
      "title": "PRE-ProstAtectomy MRI-GuidEd Stereotactic Body RadioTherapy for High-Risk Prostate Cancer Trial (PREPARE SBRT)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "5 Gy x 5 fractions",
          "type": "RADIATION"
        },
        {
          "name": "6 Gy x 5 fractions",
          "type": "RADIATION"
        },
        {
          "name": "6.5 Gy x 5 fractions",
          "type": "RADIATION"
        },
        {
          "name": "maximum tolerated dose (6.5 Gy x 5 fractions)",
          "type": "RADIATION"
        },
        {
          "name": "recommended phase 2 dose (6.5 Gy x 5 fractions)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "MALE",
        "summary": "18 Years to 90 Years · Male only"
      },
      "enrollment_count": 16,
      "start_date": "2018-10-24",
      "completion_date": "2027-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-11-20T02:08:54.400Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03663218"
    },
    {
      "nct_id": "NCT05108233",
      "title": "Evaluation of Sleep Quality in Head and Neck Cancer Patients Throughout Treatment Course",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Malignant Head and Neck Neoplasm"
      ],
      "interventions": [
        {
          "name": "Survey Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2022-01-01",
      "completion_date": "2025-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-09-29",
      "last_synced_at": "2026-11-20T02:08:54.400Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05108233"
    },
    {
      "nct_id": "NCT02213133",
      "title": "Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Selinexor (KPT-330)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Karyopharm Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2014-09-22",
      "completion_date": "2015-12-10",
      "has_results": true,
      "last_update_posted_date": "2023-01-26",
      "last_synced_at": "2026-11-20T02:08:54.400Z",
      "location_count": 17,
      "location_summary": "Aurora, Colorado • Tampa, Florida • Evanston, Illinois + 11 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02213133"
    },
    {
      "nct_id": "NCT02329847",
      "title": "A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hematologic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 144,
      "start_date": "2015-03-11",
      "completion_date": "2022-02-09",
      "has_results": true,
      "last_update_posted_date": "2025-05-25",
      "last_synced_at": "2026-11-20T02:08:54.400Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02329847"
    },
    {
      "nct_id": "NCT06932549",
      "title": "Engaging Partners in Caring Communities",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Disease Prevention"
      ],
      "interventions": [
        {
          "name": "Technical assistance is designed to integrate Expert Recommendations for Implementing Change (ERIC) strategies, and Getting To Outcomes-TA.",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Tennessee State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 320,
      "start_date": "2025-06-01",
      "completion_date": "2026-04-01",
      "has_results": false,
      "last_update_posted_date": "2025-04-17",
      "last_synced_at": "2026-11-20T02:08:54.400Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06932549"
    },
    {
      "nct_id": "NCT00586443",
      "title": "BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "bevacizumab, everolimus, panitumumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Herbert Hurwitz, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2007-11",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2014-11-19",
      "last_synced_at": "2026-11-20T02:08:54.400Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00586443"
    },
    {
      "nct_id": "NCT03262415",
      "title": "PRECISION Study: Evaluating the Accuracy of the LabPatch Continuous Glucose Monitor",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Type1 Diabetes Mellitus",
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "LabPatch Continuous Glucose Monitoring (CGM)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Joslin Diabetes Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 30,
      "start_date": "2017-02-17",
      "completion_date": "2019-05-22",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-11-20T02:08:54.400Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03262415"
    },
    {
      "nct_id": "NCT06805825",
      "title": "A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastrointestinal Stromal Tumors",
        "Small-cell Lung Cancer",
        "Adenoid Cystic Carcinoma",
        "Uveal Melanoma",
        "Neuroendocrine Tumors",
        "Chromophobe Renal Cell Carcinoma",
        "Clear Cell Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "NN3201",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novelty Nobility, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2025-02-03",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-13",
      "last_synced_at": "2026-11-20T02:08:54.400Z",
      "location_count": 5,
      "location_summary": "Ann Arbor, Michigan • Cleveland, Ohio • Portland, Oregon + 2 more",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06805825"
    },
    {
      "nct_id": "NCT07787117",
      "title": "QUARTZ: Comparative Effectiveness of Switching From Albuterol to Albuterol/Budesonide Versus Adding Low-dose ICS or LTRA to Albuterol",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "None (observational study)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 8681,
      "start_date": "2026-08-03",
      "completion_date": "2026-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-26",
      "last_synced_at": "2026-11-20T02:08:54.400Z",
      "location_count": 1,
      "location_summary": "Wilmington, Delaware",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07787117"
    },
    {
      "nct_id": "NCT02998450",
      "title": "A Study of IMR-687 in Healthy Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Sickle-Cell; Hb-SC",
        "Sickle Beta 0 Thalassemia"
      ],
      "interventions": [
        {
          "name": "IMR-687",
          "type": "DRUG"
        },
        {
          "name": "Placebo Oral Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cardurion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 66,
      "start_date": "2016-10-18",
      "completion_date": "2017-07-08",
      "has_results": false,
      "last_update_posted_date": "2025-05-15",
      "last_synced_at": "2026-11-20T02:08:54.400Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02998450"
    }
  ]
}